ICD (see Implantable cardiac defibrillators (ICD); Implantable cardioverter-defibrillator (ICD))

ICD therapy, indications for, 325

ICF (see Intracellular fluid (ICF))

ICH (see International Conference on Harmonization (ICH))

ICS (see Inhaled corticosteroids (ICS))

Icterus, 972

ICU (see Intensive care unit (ICU))

ICU-acquired weakness

incidence of, 47

risk factors for, 47

ID (see Intellectual disability (ID))

Ideal body weight (IBW), 184

IDH (see Intradialytic hypotension (IDH))

Idiopathic dyspepsia (see Functional dyspepsia)

Idiopathic rhinitis

diagnosis of, 447

therapeutic agents in, 447–448

Idiopathic RPGN, 641

Idiopathic thrombocytopenia purpura (ITP), 1972

IDL (see Intermediate-density lipoproteins (IDL))

IDSA (see Infectious Diseases Society of America (IDSA))

IE (see Infective endocarditis (IE))

IEPS (see Interdisciplinary Education Perception Scale (IEPS))

IFALD (see Intestinal failure–associated liver disease (IFALD))

IFG (see Impaired fasting glucose (IFG))

IFIs (see Invasive fungal infections (IFIs))

IgA (see Immunoglobulin A (IgA))

IgE (see Immunoglobulin E (IgE))

IGT (see Impaired glucose tolerance (IGT))

IHS (see Inhalation of hypertonic saline (IHS); International Headache Society (IHS))

IIEF (see International Index of Erectile Function (IIEF))

IMA (see Internal mammary artery (IMA))

Immediate hypersensitivity reactions, 682

Immune complex–mediated reactions, 683

Immune-modulating pulmonary formula (IMP), 779, 780

Immune reconstitution inflammatory syndrome (IRIS), 1441

Immunization, 1352

and administration techniques, 1363–1364, 1364t

and adverse reactions, 1353

contraindications for, 1353

and HAV, 1666

for HBV, 1674

inactivated vaccines for

diphtheria/tetanus/pertussis, 1357

Haemophilus influenzae b, 1357–1358

hepatitis A, 1356–1357

hepatitis B, 1355–1356

human papillomavirus, 1359–1360

influenza, 1360–1361

meningococcus, 1359

pneumococcus, 1360

polio, 1358–1359

legal requirements for, 1364–1365

live attenuated vaccines for, 1361–1363

measles/mumps/rubella, 1362

rotavirus, 1361–1362

varicella, 1362–1363

malaria, 1701

principles related to, 1353–1354

schedule for, 1355

vaccines for, 1353, 1354t

Immunoglobulin A (IgA), 428

Immunoglobulin E (IgE), 378

Immunoglobulins, 27, 742

for neutropenic cancer patient, 1570

Immunomodulators, 523–524

Immunoreactive arthropathy, 454

Immunoreactive trypsin (IRT) levels, 456

Immunosuppressants

for systemic lupus erythematosus, 709

Immunosuppressive agents, 718, 719t

antithymocyte globulins, 722–723

azathioprine, 718, 720–721

belatacept, 722

calcineurin inhibitors, 721–722

corticosteroids, 721

interactions, 739t

monoclonal antibodies, 723

mTOR inhibitors, 722, 731–732

mycophenolate mofetil and mycophenolate sodium, 721

polyclonal antibodies, 722–723

Immunosuppressive therapy, 724–725

IMP (see Immune-modulating pulmonary formula (IMP))

Impaired fasting glucose (IFG), 1072

Impaired glucose tolerance (IGT), 1009–1010, 1072

Impedance plethysmography, for DVT, 183

Impella, adverse effects of, 366

Implanon, 948

Implantable cardiac defibrillators (ICD), 325–326

Implantable cardioverter-defibrillator (ICD), 272

Indirect calorimetry, 751–752

Induction therapy, 725

Indwelling nasogastric tube (NG), 547

Infants

and acidosis, 2148

administration of medications

oral, 2155, 2155f

otic, ophthalmic, and nasal medications, 2155–2156, 2156f

and amino acid formulations, 2150–2151

azotemia in, 2148

and BPD, 2150

care for

common cold and cough, 2157–2158

constipation, 2158, 2159t

dehydration, 2160

diaper rash, 2156

febrile seizures, 2157

fever, 2156–2157

gastroenteritis, 2159–2161, 2161t

vomiting and diarrhea, 2158–2159

a

n

d

c

a

r

nit

in

e

d

e

fic

ie

n

c

y

,

2

1

5

1

a

n

d

c

h

e

mo

th

e

r

a

p

y

do

s

a

g

e

,

2

0

0

7

a

n

d

c

hr

o

nic

h

e

p

a

t

ic

dis

e

a

s

e

,

2

1

4

8

–

2

1

4

9

c

o

mp

lic

a

t

io

n

s

a

s

s

o

c

ia

t

e

d

w

ith

b

r

e

a

s

t

-

fe

e

din

g

,

2

1

4

4

a

n

d

dia

r

r

h

e

a

,

2

1

5

8

–

2

1

5

9

e

nt

e

r

a

l

nutr

it

io

n

,

2

1

4

3

–

2

1

5

2

b

r

e

a

s

t

fe

e

din

g

,

2

1

4

3

–

2

1

4

5

,

2

1

4

4

t

a

n

d

c

a

rb

o

hy

dr

a

t

e

a

b

s

o

rp

t

io

n

,

2

1

4

7

a

n

d

fo

r

mula

int

o

le

r

a

n

c

e

,

2

1

4

7

hyp

e

r

t

o

nic

fo

r

mula

s

,

2

1

4

7

la

c

t

o

s

e

-

fr

e

e

fo

r

mula

,

2

1

4

7

ma

n

a

g

e

me

nt

o

f

me

t

a

b

o

lic

e

r

r

o

r

s

,

2

1

4

5

nutr

it

io

n

a

l

a

s

s

e

s

s

me

nt

,

2

1

4

6–

2

1

4

8

p

h

e

ny

la

la

nin

e

-

fr

e

e

th

e

r

a

p

e

ut

ic

fo

r

mula

s

,

2

1

4

5

p

ur

e

c

o

w

’

s

milk

,

2

1

4

5

r

e

a

dy

-

t

o

-

fe

e

d

fo

r

m

fe

e

d

s

,

2

1

4

5

r

o

ut

e

o

f

a

dminis

tr

a

t

io

n

,

2

1

4

6

,

2

1

4

7

t

s

o

lid

fo

o

d

s

,

2

1

4

5

s

o

y

-

b

a

s

e

d

fo

r

mula

s

,

2

1

4

4

th

e

r

a

p

e

ut

ic

fo

r

mula

s

,

2

1

4

5

–

2

1

4

6

e

s

s

e

nt

ia

l

a

min

o

a

c

id

s

fo

r

,

2

1

5

0

a

n

d

fa

t

e

muls

io

n

c

o

mp

lic

a

t

io

n

s

,

2

1

4

9

p. 2

3

4

6

p. 2

3

4

7

a

n

d

fo

r

mula

int

o

le

r

a

n

c

e

,

2

1

4

7

fo

r

mula

s

fo

r

,

2

1

4

4

t

g

a

s

tr

o

e

s

op

h

a

g

e

a

l

r

e

flux

(

GE

R

)

dis

e

a

s

e

,

2

1

6

1

–

2

1

6

4

a

n

d

g

a

s

tr

o

int

e

s

t

in

a

l

(

GI

)

a

n

o

ma

lie

s

,

2

1

4

8

a

n

d

g

lu

c

o

s

e

int

o

le

r

a

n

c

e

,

2

1

5

0

intr

o

du

c

t

io

n

o

f

s

o

lid

fo

o

d

s

,

2

1

4

5

a

n

d

milk–

b

a

s

e

d

die

t

,

2

1

4

3

–

2

1

4

5

,

2

1

4

4

t

nutr

it

io

n

a

l

s

t

a

tu

s

,

2

1

4

6–

2

1

4

7

a

n

d

o

r

a

l

r

e

p

la

c

e

me

nt

th

e

r

a

p

y

,

2

1

6

0–

2

1

6

1

,

2

1

6

1

t

p

a

r

e

nt

e

r

a

l

nutr

ie

nt

r

e

g

ime

n

fo

r

,

2

1

4

8

,

2

1

5

1

–

2

1

5

2

c

a

lc

ium

c

o

nt

e

nt

,

2

1

5

1

w

ith

c

hr

o

nic

r

e

n

a

l,

2

1

4

8

–

2

1

4

9

fa

t

e

muls

io

n

c

o

mp

lic

a

t

io

n

s

,

2

1

4

9

w

ith

GI

a

n

o

ma

lie

s

,

2

1

4

8

g

o

a

ls

o

f,

2

1

4

9

w

ith

h

e

p

a

t

ic

dis

e

a

s

e

,

2

1

4

8

–

2

1

4

9

a

n

d

liv

e

r

dis

e

a

s

e

s

,

2

1

5

1

–

2

1

5

2

w

ith

r

e

s

p

ir

a

t

o

r

y

dis

tr

e

s

s

,

2

1

4

8

fo

r

v

e

r

y

lo

w

-

b

ir

th

-

w

e

ight

(

V

L

B

W

)

,

2

1

4

8

p

e

dia

tr

ic

a

min

o

a

c

id

fo

r

mula

t

io

n

s

(

P

A

A

F

s

)

,

2

1

5

0

a

n

d

p

ur

e

c

o

w

’

s

milk

,

2

1

4

5

a

n

d

r

e

s

p

ir

a

t

o

r

y

dis

tr

e

s

s

,

2

1

4

8

a

n

d

r

ic

ke

t

s

,

2

1

5

1

a

n

d

r

is

k

fo

r

hyp

o

g

ly

c

e

mia

,

9

7

9

s

e

p

s

is

a

n

d

s

e

p

t

ic

s

h

o

c

k

in

,

2

2

0

2

–

2

2

0

5

,

2

2

0

3

t

,

2

2

0

4

t

,

2

2

0

5

t

c

a

r

dio

v

a

s

c

ula

r

drug

th

e

r

a

p

y

,

2

2

0

6–

2

2

0

9

,

2

2

0

7

t

c

o

r

t

ic

o

s

t

e

r

o

id

th

e

r

a

p

y

,

2

2

0

9

ma

n

a

g

e

me

nt

,

2

2

0

5

–

2

2

0

6